Topiramate (All indications) updated on 04-22-2025

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18704
R79577		 Mazzone (Topiramate) (Controls exposed to LTG) (Mixed indications), 2025 Low birth weight during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 0.78 [0.49;1.26] C
excluded (control group) 		22/391   104/1,469 126 391
ref
S18705
R79584		 Mazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 Low birth weight during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.02 [0.58;1.78] 22/391   30,896/624,794 30,918 391
ref
S16072
R66697		 Christensen (Topiramate) (All indications) (Controls exposed to LTG), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.42 [1.01;1.98] C
excluded (control group) 		40/638   395/8,756 435 638
ref
S16040
R66577		 Christensen (Topiramate) (All indications) (Controls unexposed, general population), 2024 Low birth weight (<2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.51 [1.09;2.10] 40/638   141,442/4,467,848 141,482 638
ref
S10103
R36815		 Coste (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No 1.10 [0.74;1.62] C
excluded (control group) 		32/477   179/2,916 211 477
ref
S8613
R28733		 Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.27 [0.89;1.82] C 32/477   91,455/1,710,441 91,487 477
ref
S8599
R28628		 Hernández-Díaz (Topiramate) (Mixed indications) (Controls exposed to Lamotrigine, sick), 2014 Low birth weight (< 2500g) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No 1.86 [1.19;2.90] C
excluded (control group) 		29/347   74/1,581 103 347
ref
S8600
R28631		 Hernández-Díaz (Topiramate) (Mixed indications) (Controls unexposed, disease free), 2014 Low birth weight (< 2500g) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No 2.22 [1.21;4.08] C 29/347   18/457 47 347
ref
Total 4 studies 1.42 [1.11;1.81] 263,934 1,853
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Mazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025Mazzone, 2025 1 1.02[0.58; 1.78]30,91839116%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Christensen (Topiramate) (All indications) (Controls unexposed, general population), 2024Christensen, 2024 2 1.51[1.09; 2.10]141,48263837%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020Coste, 2020 3 1.27[0.89; 1.82]91,48747733%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Hernández-Díaz (Topiramate) (Mixed indications) (Controls unexposed, disease free), 2014Hernández-Díaz, 2014 4 2.22[1.21; 4.08]4734714%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Total (4 studies) I2 = 24% 1.42[1.11; 1.81]263,9341,8530.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Topiramate) (Controls unexposed, NOS) (Mixed indications; 2: Topiramate) (All indications) (Controls unexposed, general population; 3: Topiramate) (Controls unexposed, NOS) (Mixed indications; 4: Topiramate) (Mixed indications) (Controls unexposed, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.42[1.11; 1.81]263,9341,85324%NAMazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 Christensen (Topiramate) (All indications) (Controls unexposed, general population), 2024 Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 Hernández-Díaz (Topiramate) (Mixed indications) (Controls unexposed, disease free), 2014 4 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.42[1.11; 1.81]263,9341,85324%NAMazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 Christensen (Topiramate) (All indications) (Controls unexposed, general population), 2024 Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 Hernández-Díaz (Topiramate) (Mixed indications) (Controls unexposed, disease free), 2014 4 Tags Adjustment   - No  - No 1.59[0.93; 2.72]91,53482459%NACoste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 Hernández-Díaz (Topiramate) (Mixed indications) (Controls unexposed, disease free), 2014 2   - Yes  - Yes 1.33[0.93; 1.91]172,4001,02929%NAMazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 Christensen (Topiramate) (All indications) (Controls unexposed, general population), 2024 2 All studiesAll studies 1.42[1.11; 1.81]263,9341,85324%NAMazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 Christensen (Topiramate) (All indications) (Controls unexposed, general population), 2024 Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 Hernández-Díaz (Topiramate) (Mixed indications) (Controls unexposed, disease free), 2014 40.55.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.01.10.3710.000Mazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025Christensen (Topiramate) (All indications) (Controls unexposed, general population), 2024Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020Hernández-Díaz (Topiramate) (Mixed indications) (Controls unexposed, disease free), 2014

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 8599, 10103, 16072, 18704

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.42[1.11; 1.81]263,9341,85324%NAMazzone (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2025 Christensen (Topiramate) (All indications) (Controls unexposed, general population), 2024 Coste (Topiramate) (Controls unexposed, NOS) (Mixed indications), 2020 Hernández-Díaz (Topiramate) (Mixed indications) (Controls unexposed, disease free), 2014 4 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.24[0.89; 1.72]8751,85361%NAMazzone (Topiramate) (Controls exposed to LTG) (Mixed indications), 2025 Christensen (Topiramate) (All indications) (Controls exposed to LTG), 2024 Coste (Topiramate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2020 Hernández-Díaz (Topiramate) (Mixed indications) (Controls exposed to Lamotrigine, sick), 2014 40.510.01.0